

3-3-05

1642
CW

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	09/806,125	
	Filing Date	3/28/2001	
	First Named Inventor	MATSUTANI, Eisuya	
	Art Unit	1642	
	Examiner Name	Rawlings, S.	
Total Number of Pages in This Submission	11	Attorney Docket Number	2556 US0P

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below): Return Postcard; Certificate of Express Mailing
Remarks The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account 500799.		


SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm Name	Takeda Pharmaceuticals North America	
Signature		
Printed name	Mark Chao, Ph.D., JD	
Date	3/1/05	Reg. No. 37,293

CERTIFICATE OF TRANSMISSION/MAILING		
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as <u>first class</u> mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: <u>Express</u>		
Signature		
Typed or printed name	Gail L. Winokur	Date 3/1/05

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Express Mail # EV524907685 US



THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 09/806,125

Filed: 3/28/2001

1st Inventor: MATSUTANI, Eisuya

For: Agent that Retards the Transformation of Hormone-dependent Cancer to Non-hormone Dependent Cancer

Atty. Dkt. No. 2556 USOP

Art Unit: 1642

Examiner: Rawlings, S.

Allowed:

Batch:

Paper No.:

CERTIFICATE OF EXPRESS MAILING UNDER 37 CFR 1.10

USPS EXPRESS MAIL LABEL. No. EV 524907685 US

DATE IN: March 1, 2005

Itemized Papers/Items:


1. This Certificate of Express Mailing and Return Postcard (2 pages)
2. Transmittal Form (1 page X 2)
3. Response to Notice of Non-Responsive Amendment and Notice to Comply with Sequence Listing Requirements/Amendment "B" (7 pages)

The undersigned hereby certifies that the above itemized papers are together being deposited with the Express Mail Post Office to Addressee service of the United States Postal Service (USPS) in an envelope with sufficient postage, having the USPS Express Mail Label No. shown above, and addressed to:


MAIL STOP SEQUENCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on this date, 3/1/05

Dated: 3/1/05


Gail L. Winokur

Takeda Pharmaceuticals North America, Inc.
Intellectual Property Department
475 Half Day Road
Lincolnshire, IL 60069 USA



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 09/806,125

Filed: 3/28/2001

1st Inventor: MATSUTANI, Eisuya

For: Agent that retards the transformation of
hormone-dependent cancer to non-hormone
dependent cancer

Atty. Dkt. No. 2556 USOP

Art Unit: 1642

Examiner: Rawlings, S.

Allowed:

Batch:

Paper No.:

**Response to Notice of Non-Responsive Amendment and
Notice to Comply with Sequence Listing Requirements**

AMENDMENT "B"

MAIL STOP SEQUENCE
Commissioner for Patents
P.O. Box 1450
Arlington, VA 22313-1450

Sir:

In response to the Notice of Incomplete Response dated 2/18/2005, with regard to the
Notice to Comply mailed October 7, 2004, Applicants make the following amendments.

I. In the Specification

Applicants ask that the following amendment to the specification be made to overcome
the Examiner's objections.

On Page 2, substitute the following for Paragraph [006]: